Unum Group (NYSE:UNM) Price Target Raised to $70.00

Unum Group (NYSE:UNM) had its price objective hoisted by analysts at Truist Financial from $62.00 to $70.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the financial services provider’s stock. Truist Financial’s target price points to a potential upside of 21.63% from the company’s current price.

Other analysts have also issued research reports about the stock. Morgan Stanley upped their target price on shares of Unum Group from $50.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Monday, April 15th. JPMorgan Chase & Co. increased their price target on shares of Unum Group from $64.00 to $65.00 and gave the stock an “overweight” rating in a report on Wednesday. Piper Sandler began coverage on shares of Unum Group in a research note on Thursday, July 11th. They issued an “overweight” rating and a $57.00 target price on the stock. Jefferies Financial Group lifted their price target on shares of Unum Group from $63.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. Finally, Citigroup lifted their price target on shares of Unum Group from $62.00 to $69.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Unum Group currently has a consensus rating of “Moderate Buy” and an average target price of $61.44.

Unum Group Trading Up 0.0 %

Shares of NYSE:UNM traded up $0.02 during trading on Thursday, reaching $57.55. The stock had a trading volume of 105,989 shares, compared to its average volume of 1,263,412. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.28 and a current ratio of 0.28. Unum Group has a 52 week low of $41.75 and a 52 week high of $58.17. The firm’s fifty day moving average is $51.87 and its 200 day moving average is $50.93. The stock has a market cap of $10.90 billion, a price-to-earnings ratio of 8.55, a P/E/G ratio of 1.08 and a beta of 0.81.

Unum Group (NYSE:UNM) last released its quarterly earnings data on Tuesday, July 30th. The financial services provider reported $2.16 earnings per share for the quarter, topping the consensus estimate of $2.02 by $0.14. Unum Group had a net margin of 10.40% and a return on equity of 15.80%. The firm had revenue of $3.23 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter in the prior year, the company posted $2.06 earnings per share. The business’s revenue was up 3.9% on a year-over-year basis. As a group, equities analysts forecast that Unum Group will post 8.25 EPS for the current fiscal year.

Insider Activity at Unum Group

In other news, Director Timothy F. Keaney sold 8,000 shares of the company’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $52.61, for a total value of $420,880.00. Following the sale, the director now directly owns 37,505 shares of the company’s stock, valued at approximately $1,973,138.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Christopher W. Pyne sold 4,500 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $52.47, for a total value of $236,115.00. Following the completion of the sale, the executive vice president now directly owns 56,262 shares in the company, valued at $2,952,067.14. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Timothy F. Keaney sold 8,000 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $52.61, for a total value of $420,880.00. Following the completion of the sale, the director now owns 37,505 shares of the company’s stock, valued at $1,973,138.05. The disclosure for this sale can be found here. 0.93% of the stock is currently owned by company insiders.

Institutional Trading of Unum Group

A number of institutional investors have recently bought and sold shares of UNM. Norges Bank bought a new stake in Unum Group in the fourth quarter worth $590,489,000. Nordea Investment Management AB increased its stake in shares of Unum Group by 51.7% during the first quarter. Nordea Investment Management AB now owns 2,961,539 shares of the financial services provider’s stock valued at $158,590,000 after buying an additional 1,008,776 shares during the period. ProShare Advisors LLC increased its stake in shares of Unum Group by 6,498.1% during the first quarter. ProShare Advisors LLC now owns 636,320 shares of the financial services provider’s stock valued at $34,145,000 after buying an additional 626,676 shares during the period. Assenagon Asset Management S.A. grew its stake in Unum Group by 85.0% in the first quarter. Assenagon Asset Management S.A. now owns 778,129 shares of the financial services provider’s stock valued at $41,754,000 after purchasing an additional 357,475 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in Unum Group by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 20,590,655 shares of the financial services provider’s stock valued at $931,109,000 after purchasing an additional 300,840 shares during the last quarter. 86.57% of the stock is currently owned by institutional investors.

Unum Group Company Profile

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.